WO1992012702A1 - Kosmetisches oder pharmazeutisches mittel - Google Patents
Kosmetisches oder pharmazeutisches mittel Download PDFInfo
- Publication number
- WO1992012702A1 WO1992012702A1 PCT/EP1992/000076 EP9200076W WO9212702A1 WO 1992012702 A1 WO1992012702 A1 WO 1992012702A1 EP 9200076 W EP9200076 W EP 9200076W WO 9212702 A1 WO9212702 A1 WO 9212702A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tocopherol
- silymarin
- cosmetic
- flavolignan
- alcohol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
Definitions
- the invention relates to a cosmetic or pharmaceutical agent / which contains a flavolignan and tocopherol or an ester thereof.
- Oxidative and reductive processes in the cellular area play a central role in metabolism. This results in highly reactive / short-lived metabolic intermediates / namely free radicals.
- Oxygen Congressls / such as the super oxide radical anion / the hydroperoxide radical and the hydroxyl radical / play a special role here.
- Free radicals can generally be generated in the cell by a variety of environmental reactions or substances.
- One possibility for this is photolysis by UV radiation. It is considered certain that UV radiation, which can penetrate into the upper cell layers, is involved in the development of malignant skin carcinomas and the aging of the skin.
- reducing radical scavengers which include, for example, vitamins C and E and silymarin.
- EP-A-180 505 describes a cosmetic agent in two parts for delaying the aging of the skin.
- the one, hydrophilic part comprises an active ingredient, which can be, inter alia, silymarin.
- the other, hydrophobic part of the composition comprises, for example, unsaponifiable soy constituents, unsaponifiable avocado constituents, nut oil, etc.
- FR-A-2 597 337 also describes a cosmetic agent for delaying the aging of the skin. This too
- Agent is in two parts, one part containing numerous components, including silymarin.
- the oil-soluble part also contains numerous constituents, of course tocopherols are also mentioned. Because the agent is made up in two parts, more of the active ingredient should be able to be dissolved in the oily and aqueous phase.
- the invention therefore relates to a cosmetic or pharmaceutical composition which contains at least one flavolignan and tocopherol and / or an ester thereof.
- the flavolignans used in the agent according to the invention are, in particular, silymarin or derivatives thereof.
- Silymarin is extracted from the silver thistle Silibu marianum. It is a mixture of several flavolignans, namely silibin, silibinin, silidianin and silichristin.
- the preparation and recovery of the silymarin extract and the individual compounds are described, for example, in DE-A-19 23 082, DE-A-29 14 330, DE-A-35 37 656 and drug research. 24, No. 4, 466-471 (1974).
- silymarin derivatives are in particular salts and Addition compounds (complex compounds) of silymarin, such as the salts of silymarin with monoaminopolyhydroxy alcohols, for example 1-methylaminoglucose, described in DE-A-23 02 593; Silibinin hemisuccinate and silymarin-cyclodextri complexes, as described in EP-A-90 118 964. Reference is made in full to the content of the applications mentioned.
- silymarin mixture and one or more of the individual compounds can be used in the agents according to the invention.
- the flavolignans, and in particular silymarin can also be used in the form of addition salts.
- the tocopherols used according to the invention are compounds with a vitamin E character. These are ⁇ -, ⁇ - ⁇ - and ⁇ -tocopherol, with ⁇ -tocopherol being preferred.
- the agents according to the invention also contain a protein hydrolyzate.
- the molecular weight of the protein hydrolyzate is generally in the range of 300-50,000, in particular 500-25,000, Dalto.
- the protein hydrolyzates can originate from vegetable or animal protein, e.g. of wheat or soy protein, collagen, etc. Suitable protein hydrolyzates are commercially available, e.g. Gluadin AGP (Henkel), obtained by enzymatic hydrolysis of wheat protein, pH 4.5-5.0 (10% solution), molecular weight 2000-25000, or Nutrilan L (Henkel), obtained by acid Hydrolysis of collagen, pH 5.5 - 6.5, molecular weight 500 - 2000.
- the agents according to the invention contain at least one amino acid, - especially methionine or cysteine.
- An amino acid mixture is expediently used, for example the commercially available product ASM-Cl (from Degussa) with the following amino acids
- the quantitative ratio of flavolignan to tocopherol or an ester thereof can vary within a wide range.
- the amount by weight of tocopherol or an ester thereof to flavolignan is in the range from 5: 1 to 20: 1, in particular 10: 1 to 20: 1.
- the weight ratio of tocopherol or an ester thereof to protein hydrolyzate or amino acid (mixture) is generally 2: 1 to 15: 1, in particular 3: 1 to 10 :1.
- the agents according to the invention can contain conventional additives.
- skin care products such as cationic quaternary polymers;
- Moisturizing agents such as glycerol, sorbitol, pentaerythritol, inositol, pyrrolidonecarboxylic acid and the salts thereof; artificial tanning agents, such as dihydroxyacetone, erythrulose, glyceraldehyde, ⁇ -dialdehydes, such as 2,3-dihydroxysuccinaldehyde, optionally together with other dyes for the skin; Sunscreen; Antiperspirants; Deodorants; astringent agents; refreshing and strengthening products; Extracts from animal and vegetable tissues; Perfume waters; Dyes; unsaturated higher fatty acids, vitamins, hormones, antibiotics etc.
- agents according to the invention can be used in particular in a
- topical administration form For this purpose it is generally used in the form of a cream, solution, gel or emulsion.
- the agents can also contain customary adjuvants for this, for example preservatives, sequestering agents, thickeners, emulsifiers, etc.
- the carrier can be formulated on the basis of soaps or fatty alcohols in the presence of emulsifiers.
- the soaps can originate from natural or synthetic C, -, - C, "- fatty acids (e.g. lauric acid, myristic acid, palmitic acid, stearic acid) in an amount of 10 to 30% by weight as well as alkalizing agents (such as sodium hydroxide / potassium hydroxide / ammonia / Mono ethanolamine, diethanola in, triethanolamine).
- the creams can also contain adjuvants such as fatty amides and fatty alcohols.
- fatty amides are, in particular, mono- or diethanolamides of coconut fatty acids, lauric acid or oleic acid in an amount of up to 10% by weight / based on the total weight of the agent.
- Usable fatty alcohols are in particular oleyl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol or isostearyl alcohol in an amount of up to 10% by weight / based on the total weight of the agent.
- the creams can also be based on natural or synthetic C. 2 -C. g -alcohols can be formulated together with emulsifiers.
- Usable fatty alcohols are in particular coconut oil alcohol, myristyl alcohol, cetyl alcohol / stearyl alcohol / hydroxystearyl alcohol in an amount of 5 to 25% by weight, based on the total weight of the agent.
- Oxethylated or polyglycerolated fatty alcohols for example polyethoxylated oleyl alcohol, oxyethylenated cetyl alcohol, oxyethylenated cetylstearyl alcohol, oxyethylenated oleocetyl alcohol, oxyethylenated stearyl alcohol, polyglycerated oleyl alcohol, polyoxethylenated C 8 -C. - Fatty alcohols etc.
- These non-ionic emulsifiers are generally present in an amount of 5 to 25% by weight, based on the total weight of the agent.
- esters of higher fatty acids such as stearic acid with polyalcohols, such as glycerol, sorbitol / propylene glycol / polyethylene glycols etc.
- oxyethylated alkyl sulfates such as triethanolamine, lauryl sulfate / oxyethylated sodium lauryl ether sulfate and oxyethylated monoethanolamine lauryl ether sulfate.
- Nonionic emulsions generally include oils and / or waxes / fatty alcohols, polyethoxylated fatty alcohols / such as, for example, stearyl alcohol or polyethoxylated cetylstearyl alcohol.
- Anionic emulsions are generally formulated from soaps.
- Suitable solvents for solutions and gels are water or water-alcohol mixtures, e.g. Water / ethanol or water / isopropanol.
- Suitable gelling agents are in particular
- Cellulose derivatives such as carboxymethyl cellulose, hydroxyethyl cellulose, and polyacrylic acids (e.g. carbopole).
- the in vitro investigation was carried out on human keratin cytocytes, which were used with UV-A rays to induce over free radical mediated cell damage were irradiated.
- Isolated keratinocytes from the foreskin of a two-month child were used for this purpose.
- the keratinocytes were cultivated in MCDB 153 (Irvine®) plus ethanolamine, phosphoethanolamine, cortisone, insulin, calcium (0.1 mM).
- the pituitary extract concentration was 0.5% (70 ⁇ g / ml).
- the cells are kept in Corning culture vessels with a diameter of 100 mm in a humid atmosphere with 5% CO 2 at 37 ° C.
- the keratinocytes became steady every 8 days
- the growth rate was determined colorimetrically / based on the metabolic activity of the cells using a tetrazolium salt (MTT test, Mosmann 1983). A blue color developed, the intensity of which is proportional to the cell density. The absorption at 570 nm was determined spectrophotometrically.
- Phenol red to 10 ml These test solutions are used undiluted or diluted to 1/2, 1/10 and 1/20.
- Free radicals were generated by UV-A radiation using a Vilber Lourmat mercury vapor lamp
- Toxicity to keratinocytes 24 h after radiation The keratinocytes were irradiated in Hanks solution without phenol red. After the irradiation, the electrolyte solution was removed and the cells were left in their complete culture medium for 24 h. Cellular viability was then determined colorimetrically using MTT.
- test solutions diluted with Hanks solution without phenol red are added immediately before the irradiation and remain in contact with the keratinocytes for about 45 minutes.
- test solutions diluted with complete culture medium (MCDB 153) are added directly after the irradiation and remain in contact with the keratinocytes for 24 hours.
- the cultures without active ingredient solution are covered with aluminum foil during the irradiation.
- the radiation leads to an approximately 50% reduced cell
- Tocopherol acetate show no increased cell yield and therefore no protective effect. Only silibin hemisuccinate causes a slight increase in cell yield.
- the agent according to the invention (total mixture), on the other hand, increases the cell yield significantly in a dose-dependent manner. This protective effect is statistically significant compared to the individual substances (P ⁇ 0.05) and clearly superadditive. The effect of the agent can therefore be described as synergistic.
- the following examples illustrate the invention without restricting it.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4502483A JPH06504282A (ja) | 1991-01-16 | 1992-01-15 | 化粧用又は薬用製剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4101122A DE4101122A1 (de) | 1991-01-16 | 1991-01-16 | Kosmetisches oder pharmazeutisches mittel |
DEP4101122.8 | 1991-01-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992012702A1 true WO1992012702A1 (de) | 1992-08-06 |
Family
ID=6423117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1992/000076 WO1992012702A1 (de) | 1991-01-16 | 1992-01-15 | Kosmetisches oder pharmazeutisches mittel |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0567481A1 (de) |
JP (1) | JPH06504282A (de) |
CA (1) | CA2099879A1 (de) |
DE (1) | DE4101122A1 (de) |
WO (1) | WO1992012702A1 (de) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4323614A1 (de) * | 1993-07-12 | 1995-01-19 | Edelgard Schreiner | Mittel zur Stimulierung des Wachstums und der Regenerierung des Haares |
EP0659402A2 (de) * | 1993-12-21 | 1995-06-28 | INDENA S.p.A. | Karotenoide und Prokarotenoide enthaltende Zusammensetzungen kombiniert mit Polyphenolen zur Vorbeugung von durch abnormale freie Radikalbildung verursachten Schäden |
DE4431251A1 (de) * | 1994-09-02 | 1996-03-07 | Audor Pharma Gmbh | Hautcreme |
WO2007039976A1 (ja) * | 2005-10-03 | 2007-04-12 | Fancl Corporation | 異常タンパク質除去用組成物 |
DE102005048780A1 (de) * | 2005-10-10 | 2007-04-12 | Beiersdorf Ag | Wasserhaltige kosmetische Zubereitung mit gelösten Flavonolignanen |
EP1837008A2 (de) * | 2006-03-21 | 2007-09-26 | Coty Prestige Lancaster Group GmbH | Kosmetikum zur nachhaltigen Behandlung tieferer Hautfalten |
DE102021122753A1 (de) | 2021-09-02 | 2023-03-02 | DR. HERMANS UG (haftungsbeschränkt) | Dermatologisches mittel |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6524599B2 (en) * | 2001-02-21 | 2003-02-25 | Skinceuticals, Inc. | Use of milk thistle extract in skin care compositions |
DE10225772A1 (de) * | 2002-06-10 | 2003-12-24 | Beiersdorf Ag | Kosmetische oder dermatologische Formulierungen zur Pflege der Haut nach einem Sonnenbad oder einer Rasur |
JP3926711B2 (ja) * | 2002-08-30 | 2007-06-06 | 株式会社ファンケル | 表皮の偏平化を予防、防止、改善する皮膚老化防止用組成物 |
JP4648669B2 (ja) * | 2004-09-24 | 2011-03-09 | 株式会社ファンケル | シリマリン含有化粧料 |
MX2007007624A (es) * | 2004-12-22 | 2007-08-03 | Gillette Co | Reduccion del crecimiento del pelo con inhibidores de survivina. |
JP4033877B2 (ja) | 2005-09-29 | 2008-01-16 | 株式会社ファンケル | I型コラーゲン産生促進用組成物 |
DE102005048779A1 (de) * | 2005-10-10 | 2007-04-12 | Beiersdorf Ag | Kosmetische Formulierungen zur Verbesserung der Hautbarrierefunktion |
DE102005048778A1 (de) * | 2005-10-10 | 2007-04-12 | Beiersdorf Ag | Kosmetische Formulierungen zur Verbesserung des Aussehens der Haut |
JP2007056035A (ja) * | 2006-10-19 | 2007-03-08 | Fancl Corp | 正常ヒト表皮角化細胞の分化抑制剤 |
JP5351414B2 (ja) * | 2006-12-25 | 2013-11-27 | 株式会社ファンケル | シリビン含有化粧料組成物 |
WO2016149685A1 (en) | 2015-03-19 | 2016-09-22 | Cydex Pharmaceuticals, Inc. | Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0236218A1 (de) * | 1986-02-24 | 1987-09-09 | Claude Bonne | Kosmetische Präparate, die einen Extrakt der Früchte der Silybum Marianum enthalten |
FR2597337A2 (fr) * | 1984-10-19 | 1987-10-23 | Courtin Olivier | Cosmetique pour retarder le vieillissement de la peau et procede d'application. |
EP0278809A1 (de) * | 1987-01-19 | 1988-08-17 | Parfums Rochas | Kosmetische oder dermatologische Präparate, die einen Extrakt der Früchte des Silybum marianum mit hohem Sylimaringehalt zusammen mit essentiellen Fettsäuren enthalten |
-
1991
- 1991-01-16 DE DE4101122A patent/DE4101122A1/de not_active Withdrawn
-
1992
- 1992-01-15 EP EP92902119A patent/EP0567481A1/de not_active Withdrawn
- 1992-01-15 CA CA002099879A patent/CA2099879A1/en not_active Abandoned
- 1992-01-15 WO PCT/EP1992/000076 patent/WO1992012702A1/de not_active Application Discontinuation
- 1992-01-15 JP JP4502483A patent/JPH06504282A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2597337A2 (fr) * | 1984-10-19 | 1987-10-23 | Courtin Olivier | Cosmetique pour retarder le vieillissement de la peau et procede d'application. |
EP0236218A1 (de) * | 1986-02-24 | 1987-09-09 | Claude Bonne | Kosmetische Präparate, die einen Extrakt der Früchte der Silybum Marianum enthalten |
EP0278809A1 (de) * | 1987-01-19 | 1988-08-17 | Parfums Rochas | Kosmetische oder dermatologische Präparate, die einen Extrakt der Früchte des Silybum marianum mit hohem Sylimaringehalt zusammen mit essentiellen Fettsäuren enthalten |
Non-Patent Citations (1)
Title |
---|
CHEMICAL ABSTRACTS, vol. 115, no. 5, 1990, Columbus, Ohio, US; abstract no. 45193Z, BISSETT, D.L. ET AL.: 'PHOTOPROTECTIVE EFFECT OF SUPEROXIDE-SCAVENGING ANTIOXIDANTS AGAINST ULTRAVIOLET RADIATION-INDUCED CHRONIC SKIN DAMAGE IN THE HAIRLESS MOUSE' * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4323614A1 (de) * | 1993-07-12 | 1995-01-19 | Edelgard Schreiner | Mittel zur Stimulierung des Wachstums und der Regenerierung des Haares |
EP0659402A2 (de) * | 1993-12-21 | 1995-06-28 | INDENA S.p.A. | Karotenoide und Prokarotenoide enthaltende Zusammensetzungen kombiniert mit Polyphenolen zur Vorbeugung von durch abnormale freie Radikalbildung verursachten Schäden |
EP0659402A3 (de) * | 1993-12-21 | 1996-12-18 | Indena Spa | Karotenoide und Prokarotenoide enthaltende Zusammensetzungen kombiniert mit Polyphenolen zur Vorbeugung von durch abnormale freie Radikalbildung verursachten Schäden. |
DE4431251A1 (de) * | 1994-09-02 | 1996-03-07 | Audor Pharma Gmbh | Hautcreme |
WO2007039976A1 (ja) * | 2005-10-03 | 2007-04-12 | Fancl Corporation | 異常タンパク質除去用組成物 |
DE102005048780A1 (de) * | 2005-10-10 | 2007-04-12 | Beiersdorf Ag | Wasserhaltige kosmetische Zubereitung mit gelösten Flavonolignanen |
EP1837008A2 (de) * | 2006-03-21 | 2007-09-26 | Coty Prestige Lancaster Group GmbH | Kosmetikum zur nachhaltigen Behandlung tieferer Hautfalten |
EP1837008A3 (de) * | 2006-03-21 | 2007-10-03 | Coty Prestige Lancaster Group GmbH | Kosmetikum zur nachhaltigen Behandlung tieferer Hautfalten |
DE102021122753A1 (de) | 2021-09-02 | 2023-03-02 | DR. HERMANS UG (haftungsbeschränkt) | Dermatologisches mittel |
Also Published As
Publication number | Publication date |
---|---|
CA2099879A1 (en) | 1992-07-17 |
DE4101122A1 (de) | 1992-07-23 |
JPH06504282A (ja) | 1994-05-19 |
EP0567481A1 (de) | 1993-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60016670T2 (de) | Kosmetische Mittel, die mindestens ein Hydroxystilben und Ascorbinsäure enthalten | |
EP1002526B1 (de) | Ein Bärentraübenextrakt und ein Reduktionsmittel enthaltende Hautdepigmentierungszusammensetzung | |
EP0799023B1 (de) | Verwendung von flavonoiden als immunmodulierende oder immunschützende agenzien in kosmetischen und dermatologischen zubereitungen | |
EP1513492B1 (de) | Mikro-emulsionen mit binärer phasen- und wirkstoffdifferenzierbarkeit, deren herstellung und deren verwendung, insbesondere zur topischen sauerstoffversorgung | |
WO1992012702A1 (de) | Kosmetisches oder pharmazeutisches mittel | |
DE69728818T2 (de) | Äusserliche Hautpflegemittel | |
DE60306565T2 (de) | Zusammensetzungen gegen Krebs zur topischen Anwendung | |
DE69913023T2 (de) | Verwendung mindestens eines Hydroxystilben in einer straffenden Zusammensetzung | |
DE60023816T2 (de) | Verwendung von Lycopin in Zusammensetzungen zur Behandlung von Hautalterungserscheinungen | |
DE10228837B4 (de) | Hautkosmetische Zusammensetzung und Verwendung der Zusammensetzung als Hautbräunungsmittel | |
DE69828485T2 (de) | Zimtsäure enthaltende kosmetische Zusammensetzung und ihre Verwendung | |
EP0545147B1 (de) | Verwendung einer Superoxiddismutase zur Verhinderung oder Verzögerung des Ergrauens von menschlichen Haaren | |
EP0506961B1 (de) | Hautpräparat zur äusserlichen anwendung | |
DE69921318T2 (de) | Tensid für äusserlich anzuwendende hautpräparate und diese beinhaltende äusserlich anzuwendende hautpräparate | |
DE3832219A1 (de) | Zusammensetzungen zur topischen anwendung mit melaninsynthese-inhibitoraktivitaet | |
DE69722557T2 (de) | Verwendung von Sericin als Antioxidantien und Tyrosinase-Inhibitoren | |
DE3629241A1 (de) | Uv-strahlung-filtrierende polyaminoamide, verfahren zu deren herstellung und verwendung derselben als haut- und haarschutz | |
DE19531893A1 (de) | Juckreizmildernde, kosmetische und/oder pharmazeutische Zusammensetzungen | |
KR100325317B1 (ko) | 식물엑기스를 함유하는 의약 내지 화장품의 여드름치료제조성물 | |
EP1361853A1 (de) | Kosmetisch wirksame zusammensetzung enthaltend extrakte aus malva sylvestris und mentha piperita | |
CH694611A5 (de) | Kosmetisch wirksame Zusammensetzung. | |
DD247845A5 (de) | Verfahren zur herstellung von praeparaten gegen akne | |
JPH05186324A (ja) | 美白化粧料 | |
DE60206450T2 (de) | Wasserlöslicher Ingwerwurzelextrakt | |
JP3415200B2 (ja) | 皮膚外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2099879 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992902119 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992902119 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1994 87723 Country of ref document: US Date of ref document: 19940415 Kind code of ref document: A |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992902119 Country of ref document: EP |